<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18136">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870790</url>
  </required_header>
  <id_info>
    <org_study_id>HEPP1511</org_study_id>
    <nct_id>NCT02870790</nct_id>
  </id_info>
  <brief_title>Expanded PrEP Implementation in Communities in NSW</brief_title>
  <acronym>EPIC-NSW</acronym>
  <official_title>Impact of the Rapid Expansion of Pre-exposure Prophylaxis (PrEP) on HIV Incidence, in a Setting With High HIV Testing and Antiretroviral Treatment Coverage, to Achieve the Virtual Elimination of HIV Transmission by 2020: a NSW HIV Strategy Implementation Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new NSW Ministry of Health HIV Strategy released on 1 December 2015 aims for the virtual
      elimination of HIV transmission in NSW by 2020. Critical to the new strategy's success is
      the population-based, targeted roll-out of HIV PrEP. PrEP involves taking one pill daily of
      co-formulated tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC). This large-scale
      study aims for the rapid roll-out of TDF/FTC to individuals at high risk of HIV, who will
      comprise mostly gay and bisexual men (GBM) but will also include small numbers of
      heterosexuals, injecting drug users, and transgender men and women. The drug will be used
      according to existing NSW Ministry of Health Guidelines. By rapidly rolling out this new
      intervention over a 12 month period, and following participants for two years on treatments,
      a reduction of about 50% in new HIV diagnoses in NSW is expected.

      The study aims to assess the incidence of HIV among PrEP study participants and measure the
      population-level impact of the rapid roll-out of PrEP on HIV diagnoses among GBM in NSW over
      a two-year period.

      It will also evaluate the rate of PrEP uptake among high risk GBM in NSW, assess the
      incidence of STI (gonorrhoea, chlamydia and infectious syphilis) among people prescribed
      PrEP and measure the effect of the rapid roll-out of PrEP on the overall number of
      notifications of gonorrhoea, chlamydia and infectious syphilis in NSW, describe patterns of
      PrEP use and medication adherence, and monitor behavioural risk practices among PrEP users.

      The main population group will be 3700 gay men at high risk of HIV infection. All procedures
      of this study are guided by the NSW Guidelines on PrEP.

      Protocol Co-Chairs Professor David Cooper, Professor Andrew Grulich. Protocol Coordinating
      Investigator: Dr. Iryna Zablotska.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HIV infection per 100 person years among study participants</measure>
    <time_frame>24 months of follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of HIV diagnoses among gay and bisexual men notified to the NSW Ministry of Health.</measure>
    <time_frame>24 months of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of STI (gonorrhoea, chlamydia and infectious syphilis) per 100 person years among study participants</measure>
    <time_frame>24 months of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>HIV</condition>
  <condition>STI</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single open-label arm. All participants receive daily oral pill containing TDF/FTC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF/FTC</intervention_name>
    <description>one pill daily</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Truvada</other_name>
    <other_name>generic TDF/FTC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV negative at enrolment, with a negative HIV test result documented within seven
             days of initiating PrEP

          -  At high and ongoing risk for acquiring HIV infection through sexual exposure (as
             defined by Behavioural Eligibility criteria presented in Appendix II and online Risk
             Assessment Questionnaire in Appendix III), OR previously a PrELUDE study participant

          -  Aged 18 years or over

          -  Live in NSW or visit NSW enough to attend clinics for follow-up assessments

          -  Willing and able to provide informed consent

          -  Medicare ineligible individuals may be enrolled if the clinical service is able to
             cover the costs of monitoring of the patient

        Exclusion Criteria:

          -  HIV-1 infected or has symptoms consistent with acute viral infection (If HIV positive
             status is not confirmed by testing, delay starting PrEP for at least one month and
             reconfirm negative HIV-1 status).

          -  Having an estimated creatinine clearance (glomerular filtration rate [GFR]) &lt;60ml/min

          -  Having or developing clinical symptoms suggestive of lactic acidosis or pronounced
             hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort,
             and weakness)

          -  Concurrently taking a nephrotoxic agent (e.g., high-dose non-steroidal
             anti-inflammatory drugs / NSAIDs)

          -  Allergic to TDF and/or FTC (based on self-report or recorded)

          -  Concurrently taking prescribed products containing FTC or TDF including ATRIPLA®,
             COMPLERA®, EMTRIVA, STRIBILD®, VIREAD; other drugs containing lamivudine; HEPSERA

          -  Factors or conditions that may compromise a participant's access to health services
             for follow-up (incarceration or planned relocation and potential absence from NSW for
             the duration of the study).

        Behavioural eligibility criteria as per NSW PrEP guidelines.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cooper, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Kirby Institute, UNSW Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Grulich, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Kirby Institute, UNSW Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iryna Zablotska, MD, PhD, MPH</last_name>
    <phone>61 2 9385 0951</phone>
    <email>izablotska@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>RPA Sexual Health</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Templeton, MBChB, PhD</last_name>
      <phone>+ 61 2 9515 1200</phone>
    </contact>
    <investigator>
      <last_name>David Templeton, MBChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital HIV, Immunology and Infectious Disease Unit</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Carr, MD</last_name>
      <phone>+61 2 8382 3707</phone>
    </contact>
    <contact_backup>
      <last_name>John McAlister, RN, MSc</last_name>
      <phone>+61 2 8382 3707</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrew Carr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John McAlister, RN, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lismore Sexual Health Clinic - Northen Rivers Area Health Service</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denni Pearson</last_name>
      <phone>+61 (02) 6620-2980</phone>
      <email>dennip@nrahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Sydney Sexual Health Centre</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catriona Ooi, MBBS, MMed</last_name>
      <phone>+61 2 9843 3124</phone>
    </contact>
    <investigator>
      <last_name>Catriona Ooi, MBBS, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kirketon Road Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>1340</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Read, MBBS, MPH</last_name>
      <phone>+61 2 9360 2766</phone>
      <email>Phillip.Read@SESIAHS.HEALTH.NSW.GOV.AU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Sydney Doctors</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Baker, MBChB, DCH, DipMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgia Smith</last_name>
    </contact>
    <investigator>
      <last_name>Mark Bloch, MBBS, DipFP, DipMedHyp, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Finlayson, MBBS, FACSHP, FAChSH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic 16, Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Hadlow</last_name>
      <phone>+61 (02) 9926-7414</phone>
      <email>Brett.Hadlow@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Linda Dayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nepean Sexual Health and HIV Clinic</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rick Varma, MbChB, MRCP, FAChSHM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 29, 2016</lastchanged_date>
  <firstreceived_date>August 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
